Patents by Inventor Miguel Jimenez

Miguel Jimenez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210342854
    Abstract: A system and method for assisting a service provider in explaining clauses of an agreement and generating an online agreement. The method includes the steps of providing a consumer interface to the consumer, the consumer interface presents the clauses to the consumer in text and audio form and can receive acceptance or rejection of the consumer in both click gesture and audio from the consumer. The video and audio can be recorded of the steps of presenting the clauses and receiving the response from the consumer.
    Type: Application
    Filed: July 13, 2021
    Publication date: November 4, 2021
    Inventor: Miguel Jimenez
  • Patent number: 11141450
    Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: October 12, 2021
    Assignee: NEKTIUM PHARMA, S.L.
    Inventors: Miguel Jiménez del Río, Julia C. Wiebe, Laura López-Ríos, Tanausú Vega Morales, Rubén Peréz Machín, Alvaro Sánchez Rodríguez, Carlos J. Mateos, Nigel Peter Gericke
  • Patent number: 11117900
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: September 14, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Chris Davis, Rebecca Davis, Steven Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Knegtel, Donald Middleton, Michael O'Donnell, Maninder Panesar, Francoise Pierard, Joanne Pinder, David Shaw, Pierre-Henri Storck, John Studley, Heather Twin
  • Publication number: 20210277372
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 9, 2021
    Inventors: Tobias A. FUCHS, Miguel JIMÉNEZ-ALCÁZAR, Josephine GÖBEL, Hanna ENGLERT
  • Patent number: 11046943
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: June 29, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Patent number: 11046942
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 29, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Publication number: 20210047333
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Application
    Filed: August 31, 2020
    Publication date: February 18, 2021
    Inventors: Nadia AHMAD, Dean BOYALL, Jean-Damien CHARRIER, Chris DAVIS, Rebecca DAVIS, Steven DURRANT, Gorka ETXEBARRIA I JARDI, Damien FRAYSSE, Juan-Miguel JIMENEZ, David KAY, Ronald KNEGTEL, Donald MIDDLETON, Michael O'DONNELL, Maninder PANESAR, Francoise PIERARD, Marie, Joanne PINDER, David SHAW, Pierre-Henri STORCK, John STUDLEY, Heather TWIN
  • Publication number: 20210040461
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Application
    Filed: October 12, 2020
    Publication date: February 11, 2021
    Inventors: Tobias A. FUCHS, Miguel JIMÉNEZ-ALCÁZAR, Josephine GÖBEL, Hanna ENGLERT
  • Publication number: 20210021655
    Abstract: In accordance with an embodiment, described herein is a system and method for streaming music on mobile devices, including those which may have limited support for streaming. In response to receiving a request for portions of media content to be retrieved from a media server and played at a media device, selected parts of a media content file (e.g., an MP3 file) can be downloaded from a media server, and prepended, appended, or otherwise adjusted into a complete (albeit relatively shorter) media content, which is decoded and sent, for example to an audio speaker at the media device. The approach provides flexibility in providing access to a media streaming service from non-native mobile device applications, for example by enabling a media application to load and play encrypted MP3 file content in environments such as mobile browsers that require low memory consumption, or do not support Media Source Extensions.
    Type: Application
    Filed: February 21, 2020
    Publication date: January 21, 2021
    Inventors: Miguel Jiménez Esún, Rafael Oleza Alomar
  • Patent number: 10874708
    Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: December 29, 2020
    Assignee: NEKTIUM PHARMA, S.L.
    Inventors: Miguel Jiménez del Rio, Julia C. Wiebe, Laura Lopez-Rios, Tanausu Vega-Morales, Ruben Perez-Machin, Alvaro Sanchez-Rodriguez, Carlos J. Mateos, Nigel Peter Gericke
  • Publication number: 20200399622
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 24, 2020
    Inventors: Tobias A. FUCHS, Miguel JIMÉNEZ-ALCÁZAR, Josephine GÖBEL, Hanna ENGLERT
  • Publication number: 20200347370
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Application
    Filed: July 15, 2020
    Publication date: November 5, 2020
    Inventors: Tobias A. FUCHS, Miguel JIMÉNEZ-ALCÁZAR, Josephine GÖBEL, Hanna ENGLERT
  • Patent number: 10801019
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: October 13, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Publication number: 20200319180
    Abstract: The present invention provides sensor cells comprising a receptor that binds to an analyte indicative of the presence of an agent, where binding of the analyte to the receptor triggers a detection event that is indicative of the presence of the agent. In certain embodiments, the detection event is appearance of a reporter detectable by the naked eye. The present invention also provides uses of such sensor cells for detecting the presence of an agent in a sample.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Virginia Wood Cornish, Nili Ostrov, Miguel Jimenez, Sonja Billerbeck
  • Patent number: 10787452
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: September 29, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Chris Davis, Rebecca Davis, Steven Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Knegtel, Donald Middleton, Michael O'Donnell, Maninder Panesar, Francoise Pierard, Joanne Pinder, David Shaw, Pierre-Henri Storck, John Studley, Heather Twin
  • Patent number: 10776075
    Abstract: A stovetop oven having an audio system comprising of a stove assembly and an audio assembly is disclosed herein. The stove assembly includes a stovetop and an oven that is configured to aid a user in cooking food. The audio assembly comprises a display unit having a processor, speakers, and a radio. The display unit displays the current media being played by a user utilizing the stove. Additionally, a user may navigate and control the audio media being played using buttons configure to the display unit. The processor allows the unit to play audio media through various forms such as WIFI, Bluetooth, and satellite radio. The radio of the audio assembly receives radio signals allows the user to tune into various radio channels for their enjoyment. The stove top oven having an audio system creates an entertaining environment for a user in the kitchen.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: September 15, 2020
    Inventor: Miguel Jimenez
  • Patent number: 10725036
    Abstract: The present invention provides sensor cells comprising a receptor that binds to an analyte indicative of the presence of an agent, where binding of the analyte to the receptor triggers a detection event that is indicative of the presence of the agent. In certain embodiments, the detection event is appearance of a reporter detectable by the naked eye. The present invention also provides uses of such sensor cells for detecting the presence of an agent in a sample.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: July 28, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Virginia Wood Cornish, Nili Ostrov, Miguel Jimenez, Sonja Billerbeck
  • Patent number: 10696956
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 30, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Publication number: 20200176070
    Abstract: Methods and apparatuses are provided for self-trimming of a semiconductor device. An example self-trimming circuit includes a control circuit configured to, during a self-trimming operation, decode a test command signal to set a target voltage and set a voltage trim code to an initial value, and to adjust a value of the voltage trim code based on a stop signal. The example self-trimming circuit further includes a reference voltage regulator configured to receive the voltage trim code and to convert a band-gap reference voltage to an output voltage based on the voltage trim code, and a comparator configured to compare the target voltage with the output voltage and to provide the stop signal having a value based on the comparison.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 4, 2020
    Applicant: MICRON TECHNOLOGY, INC.
    Inventors: Miguel Jimenez-Olivares, Maksim Kuzmenka
  • Publication number: 20200164193
    Abstract: A platform technology has been designed to provide a means for controlled delivery of single or multiple doses of therapeutic, prophylactic, diagnostic or identifying agents to livestock. The delivery system is based on a livestock ear tag that releases therapeutic and/or prophylactic agent when applied to the ear or other desired anatomical target of the animal. The agent to be delivered is encapsulated in or on microneedles and or microparticles and or nanoparticles or combination thereof on a surface thereon of the male or female part of the tag, which is pressed into the skin so that the microneedles penetrate into the epidermis and dermis layers of the skin. The agent is then released into the animal from the microneedles and or microparticles and or nanoparticles or combination thereof at the site of contact into the epidermis and dermis layers of the skin.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 28, 2020
    Inventors: Michael S. Williams, Jason Siu Wei Li, Jacob Coffey, Christoph Winfried Johannes Steiger, Miguel Jimenez, Robert S. Langer, Ester Caffarel Salvador, Alex Abramson